Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 9—September 2012
CME ACTIVITY - Policy Review

Control of Fluoroquinolone Resistance through Successful Regulation, Australia

Allen C. Cheng, John Turnidge, Peter Collignon, David Looke, Mary Barton, and Thomas GottliebComments to Author 
Author affiliations: Monash University, Melbourne, Victoria, Australia (A.C. Cheng); Alfred Hospital, Melbourne (A.C. Cheng); Women’s and Children’s Hospital, Adelaide, South Australia, Australia (J. Turnidge); University of Adelaide, Adelaide (J. Turnidge); The Canberra Hospital, Garran, Canberra, Australia (P. Collignon); Australian National University, Canberra (P. Collignon); Princess Alexandra Hospital, Brisbane, Queensland, Australia (D. Looke); University of Queensland, Brisbane (D. Looke); University of South Australia, Adelaide (M. Barton); Concord Hospital, Sydney, New South Wales, Australia (T. Gottlieb); and University of Sydney, Sydney (T. Gottlieb)

Main Article

Table 1

Quinolone antimicrobial drugs available for use in humans in Australia under the authority of the PBS*

Drug/route of administration PBS listed indication Consumer cost in AU$
Generic available
Private market† PBS GB PBS CB
Ciprofloxacin

Oral

 Respiratory tract infection proven or suspected to be caused by Pseudomonas aeruginosa in severely immunocompromised patients 25.20 34.20 5.60 Yes
Bacterial gastroenteritis in severely immunocompromised patients
Infections proven to be caused by P. aeruginosa or other gram-negative bacteria resistant to all other oral antimicrobial drugs
Joint and bone infections, epididymo-orchitis, prostatitis, or perichondritis of the pinna suspected or proven to be caused by gram-negative or -positive bacteria resistant to all other appropriate antimicrobial drugs
Gonorrhea

Topical, ear

 Treatment of chronic suppurative otitis media in Aborigines or Torres Strait Islanders >1 mo of age 24.51 19.38 5.60 No
Treatment of chronic suppurative otitis media in a patient <18 y of age with perforation of the tympanic membrane
Treatment of chronic suppurative otitis media in a patient <18 y of age with a grommet in situ

Topical, eye

 Bacterial keratitis 33.71 28.58 5.60 No
Ofloxacin

Topical, eye

 Bacterial keratitis 35.40 32.24 5.60 No
Norfloxacin

Oral

 Acute bacterial enterocolitis; complicated urinary tract infection 31.68 17.16 5.60 Yes
Moxifloxacin‡

Oral

 No longer listed 70.65 NA NA No

*PBS, Pharmaceutical Benefits Scheme; GB, general beneficiaries; CB, concessional beneficiaries, including pensioners; NA, no longer available in PBS.
†Price to consumer varies between retail outlets.
‡Data from 2011.

Main Article

Page created: August 17, 2012
Page updated: August 17, 2012
Page reviewed: August 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external